The role of ketamine in treatment-resistant depression: A systematic review

Current Neuropharmacology

Volumn 12, Issue 5, 2014, Pages 444-461

  Serafini, Gianluca ^a   Howland, Robert H ^b   Rovedi, Fabiana ^a   Girardi, Paolo ^a   Amore, Mario ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Antidepressant effect; Ketamine; NMDA receptors; Pharmacological properties; Treatment resistant depression

Indexed keywords

GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RILUZOLE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; CASE REPORT; DATA BASE; DISSOCIATIVE DISORDER; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EMERGENCY WARD; GLUCOSE METABOLISM; HUMAN; LOW DRUG DOSE; MAGNETOENCEPHALOGRAPHY; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTIPLE CYCLE TREATMENT; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; OPEN STUDY; PATHOPHYSIOLOGY; PSYCHEDELIC ACTIVITY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REPEATED DRUG DOSE; SIDE EFFECT; SUICIDAL IDEATION; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

EID: 84924141917     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X12666140619204251     Document Type: Article

References (83)

1. Soleimani, L., Lapidus, K.A., and Iosifescu, D.V. Diagnosis and treatment of major depressive disorder. Neurol. Clin. 2011, 29, 177-179. doi: 10.1016/j.ncl.2010.10.01
2. Langlieb, A.M., and Guico-Pabia, C.J. Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder. Prim. Care Companion J. Clin. Psychiatry, 2010, 12, 1-12. doi: 10.4088/PCC.09r00826blu
3. Greer, T.L., Kurian, B.T., and Trivedi, M.H. Defining and measuring functional recovery from depression. CNS Drugs, 2010, 24, 267-284. doi: 10.2165/11530230-000000000-00000.
4. Pompili, M., Iliceto, P., Luciano, D., Innamorati, M., Serafini, G., Del Casale, A., Tatarelli, R., Girardi, P., and Lester, D. Higher hopelessness and suicide risk predict lower self-deception among psychiatric patients and non-clinical individuals. Riv. Psichiatr. 2011, 46, 24-30.
5. Serafini, G., Pompili, M., Innamorati, M., Giordano, G., Montebovi, F., Sher, L., Dwivedi, Y., and Girardi, P. The role of microRNAs in synaptic plasticity, major affective disorders and suicidal behavior. Neurosci. Res. 2012, 73, 179-190. doi: 10.1016/j.neures.2012.04.001.
6. Serafini, G., Pompili, M., Innamorati, M., Fusar-Poli, P., Akiskal, H.S., Rihmer, Z., Lester, D., Romano, A., de Oliveira, I.R., Strusi, L., Ferracuti, S., Girardi, P., and Tatarelli, R. Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. J. Affect. Disord. 2011, 129, 47-55.
7. Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T., and Murray, C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 2006, 367, 1747-1757.PMID 16731270
8. Serafini, G., Pompili, M., Innamorati, M., Dwivedi, Y., Brahmachari, G., and Girardi, P. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Curr. Pharm. Des. 2013, 19, 1898- 1922. PMID: 23173582
9. Fava, M., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Alpert, J.E., McGrath, P.J., Thase, M.E., Warden, D., Biggs, M., Luther, J.F., Niederehe, G., Ritz, L., and Trivedi, M.H. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am. J. Psychiatry, 2006, 163, 1161-1172.PMID: 16816220
10. Petersen, T., Gordon, J.A., Kant, A., Fava, M., Rosenbaum, J.F., and Nierenberg, A.A. Treatment resistant depression and axis i comorbidity. Psychol. Med. 2001, 31, 1223-1239. PMID; 11681548
11. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., and Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry, 2006a, 163, 1905-1917.PMID: 17074942
12. Holtzheimer, P.E., and Mayberg, H.S. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 2011,34,1-9. doi: 10.1016/j.tins.2010.10.004
13. Crown, W.H., Finkelstein, S., Berndt, E.R., Ling, D., Poret, A.W., Rush, A.J., and Russell, J.M. The impact of treatmentresistant depression on health care utilization and costs. J. Clin. Psychiatry, 2002,63,963-971.PMID 12444808
14. Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A.A., Lebowitz, B.D., Biggs, M.M., Luther, J.F., Shores-Wilson, K., and Rush, A.J. STAR*D Study Team: Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 2006, 354, 1243-1252. PMID 16554526
15. Murrough, J.W., and Charney, D.S. Is there anything really novel on the antidepressant horizon? Curr. Psychiatry Rep. 2012, 14, 643-649. PMID: 22996298
16. Belmaker, R.H. The future of depression psychopharmacology. CNS Spectr. 2008, 13, 682-687. PMID:18704023
17. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Stewart, J.W., Nierenberg, A.A., Thase, M.E., Ritz, L., Biggs, M.M., Warden, D., Luther, J.F., Shores-Wilson, K., Niederehe, G., and Fava, M. STAR*D Study Team: Bupropion-SR, sertraline, or venlafaxine- XR after failure of SSRIs for depression. N. Engl. J. Med. 2006b, 354, 1231-1242.
18. Crane, G.E. Cyloserine as an antidepressant agent. Am. J. Psychiatry, 1959, 115, 1025-1056.PMID: 13637281
19. Crane, G.E. The psychotropic effects of cycloserine: a new use for an antibiotic. Compr. Psychiatry, 1961, 2, 51-59.
20. Krystal, J.H., Perry, E.B. Jr., Gueorguieva, R., Belger, A., Madonick, S.H., Abi-Dargham, A., Cooper, T.B., Macdougall, L., Abi-Saab, W., and D'Souza, D.C. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry, 2005,62,985-994. PMID:16143730
21. Smith, G.S., Schloesser, R., Brodie, J.D., Dewey, S.L., Logan, J., Vitkun, S.A., Simkowitz, P., Hurley, A., Cooper, T., Volkow, N.D., and Cancro, R. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology, 1998, 18,18-25. PMID:9408915
22. Vollenweider, F.X., Vontobel, P., Oye, I., Hell, D., and Leenders, K.L. Effects of (S)-ketamine on striatal dopamine: a [11C] raclopride PETstudy of a model psychosis in humans. J. Psychiatr. Res. 2000,34,35-43.PMID: 10696831
23. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Prisma Group. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. B.M.J. 2009, 339, B2535.
24. Szymkowicz, S.M., Finnegan, N., and Dale, R.M. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J. Affect. Disord. 2013, 147, 416-420. doi: 10.1016/ j.jad.2012.10.015.
25. Murrough, J.W., Perez, A.M., Mathew, S.J., and Charney, D.S. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J. Clin. Psychiatry, 2011, 72, 414-415. doi: 10.4088/JCP.10l06447blu
26. Segmiller, F., Ruther, T., Linhardt, A., Padberg, F., Berger, M., Pogarell, O., Moller, H.J., Kohler, C., and Schule, C. Repeated Sketamine infusions in therapy resistant depression: a case series. J. Clin. Pharmacol. 2013, 53, 996-998. doi: 10.1002/jcph.122
27. Messer, M., Haller, I.V., Larson, P., Pattison-Crisostomo, J., and Gessert, C.E. The use of a series of ketamine infusions in two patients with treatment-resistant depression. J. Neuropsychiatry Clin. Neurosci. 2010, 22, 442-444. doi: 10.1176/appi.neuropsych. 22.4.442
28. Paslakis, G., Gilles, M., Meyer-Lindenberg, A., and Deuschle, M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry, 2010, 43, 33-35. doi: 10.1055/s-0029-1237375
29. Liebrenz, M., Stohler, R., and Borgeat, A. Repeated intravenous ketamine therapy in a patient with a treatment-resistant major depression. World J. Biol. Psychiatry, 2009, 10, 640-643.
30. Paul, R., Schaaff, N., Padberg, F., Moller, H.J., and Frodl, T. Comparison of racemic ketamine and S-ketamine in treatmentresistant major depression: report of two cases. World J. Biol. Psychiatry, 2009, 10, 241-244. doi: 10.1080/15622970701714370
31. Mathew, S.J., Murrough, J.W., aan het Rot, M., Collins, K.A., Reich, D.L., and Charney, D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int. J. Neuropsychopharmacol. 2010, 13, 71-82.
32. Ibrahim, L., Diazgranados, N., Luckenbaugh, D.A., Machado- Vieira, R., Baumann, J., Mallinger, A.G., Zarate, C.A. Jr. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35, 1155-1159. doi: 10.1016/j.pnpbp.2011.03.019
33. Ibrahim, L., Diazgranados, N., Franco-Chaves, J., Brutsche, N., Henter, I.D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D.A., Manji, H.K., and Zarate, C.A. Jr. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebocontrolled study. Neuropsychopharmacology, 2012, 37, 1526-1533.
34. Shiroma, P.R., Johns, B., Kuskowski, M., Wels, J., Thuras, P., Albott, C.S., and Lim, K.O. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J. Affect. Disord. 2013 (in press). doi: 10.1016/j.jad.2013.10.036
35. Murrough, J.W., Perez, A.M., Pillemer, S., Stern, J., Parides, M.K., aan het Rot, M., Collins, K.A., Mathew, S.J., Charney, D.S., and Iosifescu, D.V. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry, 2013b, 74, 250-256. doi: 10.1016/ j.biopsych.2012.06.022
36. Zarate, C.A. Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, N., Luckenbaugh, D.A., Charney, D.S., and Manji, H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63, 856-864.PMID: 16894061
37. Niciu, M.J., Luckenbaugh, D.A., Ionescu, D.F., Mathews, D.C., Richards, E.M., and Zarate, C.A. Jr. Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol. Psychiatry, 2013, 74, e23-e24. doi: 10.1016/j.biopsych.2013.01.038.
38. Murrough, J.W., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Green, C.E., Perez, A.M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D.S., and Mathew, S.J. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry, 2013a, 170, 1134- 1142.
39. Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H.K., and Zarate, C.A. Jr. Brain-derived neurotrophic factor and initial antidepressant response to an Nmethyl- D-aspartate antagonist. J. Clin. Psychiatry, 2009, 70, 1662- 1666. doi: 10.4088/JCP.08m04659
40. Phelps, L.E., Brutsche, N., Moral, J.R., Luckenbaugh, D.A., Manji, H.K., and Zarate, C.A. Jr. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol. Psychiatry, 2009,65, 181-184. doi: 10.1016/j. biopsych.2008.09.029
41. Cornwell, B.R., Salvadore, G., Furey, M., Marquardt, C.A., Brutsche, N.E., Grillon, C., and Zarate, C.A. Jr. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatmentresistant major depression. Biol. Psychiatry, 2012,72, 555-561. doi: 10.1016/j.biopsych.2012.03.029
42. Murrough, J.W., Wan, L.B., Iacoviello, B., Collins, K.A., Solon, C., Glicksberg, B., Perez, A.M., Mathew, S.J., Charney, D.S., Iosifescu, D.V., and Burdick, K.E. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl), 2013c (in press).
43. Carlson, P.J., Diazgranados, N., Nugent, A.C., Ibrahim, L., Luckenbaugh, D.A., Brutsche, N., Herscovitch, P., Manji, H.K., Zarate, C.A. Jr., and Drevets, W.C. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol. Psychiatry, 2013, 73, 1213-1221.
44. Duncan, W.C. Jr., Selter, J., Brutsche, N., Sarasso, S., and Zarate, C.A. Jr. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J. Affect. Disord. 2013, 145, 115-119. doi: 10.1016/j.jad.2012.05.042
45. Price, R.B., Nock, M.K., Charney, D.S., and Mathew, S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry, 2009, 66, 522-526. doi: 10.1016/j.biopsych.2009.04.029
46. Diaz, G., N., Ibrahim, L.A., Brutsche, N.E., Ameli, R., Henter, I.D., Luckenbaugh, D.A., Machado-Vieira, R., and Zarate, C.A. Jr. Rapid resolution of suicidal ideation after a single infusion of an Nmethyl- D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry, 2010b, 71, 1605- 1611.
47. Larkin, G.L., and Beautrais, A.L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int. J. Neuropsychopharmacol. 2011, 14, 1127-1131. doi: 10.1017/S1461145711000629
48. Aan het Rot, M., Collins, K.A., Murrough, J.W., Perez, A.M., Reich, D.L., Charney, D.S., and Mathew, S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry, 2010, 67, 139-145. doi: 10.1016/j.biopsych.2009.08.038
49. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., and Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 2000, 47, 351- 354.PMID: 10686270
50. Dowben, J.S., Grant, J.S., and Keltner, N.L. Ketamine as an alternative treatment for treatment-resistant depression. Perspect. Psychiatr. Care, 2013, 49, 2-4. doi: 10.1111/ppc.12006
51. Rush, A.J. Ketamine for treatment-resistant depression: ready or not for clinical use? Am. J. Psychiatry, 2013, 170, 1079-1081.
52. Zarate, C.A. Jr., Brutsche, N.E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C.A., Liberty, V., and Luckenbaugh, D.A. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry, 2012, 71, 939-946. doi: 10.1016/j.biopsych.2011.12.010
53. Luckenbaugh, D.A., Ibrahim, L., Brutsche, N., Franco-Chaves, J., Mathews, D., Marquardt, C.A., Cassarly, C., and Zarate, C.A. Jr. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipol. Disord. 2012, 14,880-887. doi: 10.1111/bdi.12003
54. Schumann, G., Johann, M., Frank, J., Preuss, U., Dahmen, N., Laucht, M., Rietschel, M., Rujescu, D., Lourdusamy, A., Clarke, T.K., Krause, K., Dyer, A., Depner, M., Wellek, S., Treutlein, J., Szegedi, A., Giegling, I., Cichon, S., Blomeyer, D., Heinz, A., Heath, S., Lathrop, M., Wodarz, N., Soyka, M., Spanagel, R., and Mann, K. Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch. Gen. Psychiatry, 2008,65,826-838.
55. Boyce-Rustay, J.M., and Holmes, A. Ethanol-related behaviors in mice lacking the NMDA receptor NR2A subunit. Psychopharmacology (Berl.), 2006, 187,455-466. PMID: 16835771
56. Petrenko, A.B., Yamakura, T., Fujiwara, N., Askalany, A.R., Baba, H., and Sakimura, K. Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit. Anesth. Analg. 2004,99,1136-1140.PMID: 15385364
57. Chilukuri, H., Reddy, N.P., Pathapati, R.M., Manu, A.N., Jollu, S., and Shaik, A.B. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J. Psychol. Med. 2014, 36, 71-76. doi: 10.4103/0253-7176.127258
58. Grott, Z. C., Perez, D., and Glue, P. Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J. Palliat. Med. 2013,16,719-720.
59. Zanicotti, C.G., Perez, D., and Glue, P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J. Palliat. Med. 2012, 15,400-403.
60. Cusin, C., Hilton, G.Q., Nierenberg, A.A., and Fava, M. Long- Term Maintenance With Intramuscular Ketamine for Treatment- Resistant Bipolar II Depression. Am. J. Psychiatry, 2012,169,868- 869. doi: 10.1176/appi.ajp.2012.12020219
61. Mion, G., and Villevieille, T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci. Ther. 2013,19,370-380. doi: 10.1111/cns.12099.
62. Howland, R.H. Ketamine for the treatment of depression. J. Psychosoc. Nurs. Ment. Health Serv. 2013, 51, 11-14.
63. White, J.M., and Ryan, C.F. Pharmacological properties of ketamine. Drug Alcohol Rev. 1996, 15, 145-155. PMID: 16203365
64. Morgan, C.J., Muetzelfeldt, L., and Curran, H.V. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction, 2009, 104, 77-87. doi: 10.1111/j.1360-0443.2008. 02394.x.
65. Krystal, J.H., Sanacora, G., and Duman, R.S. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol. Psychiatry, 2013, 73, 1133-1141. doi: 10.1016/j.biopsych. 2013.03.026
66. Tedesco, V., Ravagnani, C., Bertoglio, D., and Chiamulera, C. Acute ketamine-induced neuroplasticity: ribosomal protein S6 phosphorylation expression in drug addiction-related rat brain areas. Neuroreport, 2013,24,388-393. doi: 10.1097/WNR. 0b013e32836131ad.
67. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., and Duman, R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 2010, 329, 959-964. doi: 10.1126/science. 1190287
68. Hayley, S., and Litteljohn, D. Neuroplasticity and the next wave of antidepressant strategies. Front. Cell. Neurosci. 2013, 7, 218. doi: 10.3389/fncel.2013.00218
69. Scheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., and Seifritz, E. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoSOne, 2012, 7, e44799.
70. Li, N., Liu, R.J., Dwyer, J.M., Banasr, M., Lee, B., Son, H., and Li, X.Y., Aghajanian G, Duman RS: Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry, 2011, 69, 754-761.
71. Liu, R.J., Lee, F.S., Li, X.Y., Bambico, F., Duman, R.S., and Aghajanian, G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry, 2012, 71, 996-1005.
72. Duman, R.S., and Li, N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2012, 367, 2475-2484. doi: 10.1098/rstb.2011.0357
73. Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F.J., Sanacora, G., and Zarate, C. Jr. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol. Psychiatry, 2012, 72, e27-e28. doi: 10.1016/j.biopsych.2012.05.031
74. Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., Kavalali, E.T., and Monteggia, L.M. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature, 2011, 475, 91-95. doi: 10.1038/nature10130
75. Tordera, R.M., Totterdell, S., Wojcik, S.M., Brose, N., Elizalde, N., Lasheras, B., and Del Rio, J. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur. J. Neurosci. 2007, 25, 281-290.PMID: 17241289
76. Farley, S., Dumas, S., El Mestikawy, S., and Giros, B. Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. Neuropharmacology, 2012, 62, 503-517. doi: 10.1016/j.neuropharm.2011.09.010
77. Garcia, L.S., Comim, C.M., Valvassori, S.S., Reus, G.Z., Stertz, L., Kapczinski, F., Gavioli, E.C., and Quevedo, J. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 450-455. doi: 10.1016/j.pnpbp.2009.01.004
78. +/_heterozygous null mice. Neuropharmacology, 2012, 62, 391-397. doi: 10.1016/j.neuropharm.2011.08.015
79. Diazgranados, N., Ibrahim, L., Brutsche, N.E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W.A., Quezado, Z., Luckenbaugh, D.A., Salvadore, G., Machado-Vieira, R., Manji, H.K., and Zarate, C.A. Jr. A randomized add-on trial of an Nmethyl- D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry, 2010a, 67, 793-802. doi: 10.1001/archgenpsychiatry.2010.90
80. Rybakowski, J.K., Permoda-Osip, A., Skibinska, M., Adamski, R., and Bartkowska-Sniatkowska, A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum. Psychopharmacol. 2013, 28, 87-90. doi: 10.1002/ hup.2271
81. Sienaert, P., Lambrichts, L., Dols, A., and De Fruyt, J. Evidencebased treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipol. Disord. 2013, 15, 61-69. doi: 10.1111/ bdi.12026.
82. Salvadore, G., Cornwell, B.R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C.A. Jr., and Manji, H.K. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry, 2009, 65, 289-295.
83. Huang, C.C., Wei, I.H., Huang, C.L., Chen, K.T., Tsai, M.H., Tsai, P., Tun, R., Huang, K.H., Chang, Y.C., Lane, H.Y., and Tsai, G.E. Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression. Biol. Psychiatry, 2013, 74, 734-741. doi: 10.1016/j.biopsych.2013.02.020